Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility

Keros Therapeutics, Inc. (KROS) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Keros Therapeutics, Inc. qualifies as a smaller reporting company and a non-accelerated filer, allowing it to provide reduced disclosures and avoid auditor attestation of internal controls under Section 404(b). An external observer notes that this lower level of transparency could make the stock less attractive to certain investors, potentially depressing liquidity and increasing share price volatility.

The average KROS stock price target is $19.00, implying 62.25% upside potential.

To learn more about Keros Therapeutics, Inc.’s risk factors, click here.